BioCryst Acquires Astria Therapeutics, Enhancing Leadership in Hereditary Angioedema with Navenibart.

BioCryst Pharmaceuticals has completed the acquisition of Astria Therapeutics, expanding its leadership in hereditary angioedema (HAE). The deal adds navenibart, a late-stage treatment for HAE, to BioCryst's portfolio. With the addition of navenibart, BioCryst can offer both oral and injectable prophylactic options for HAE patients, empowering physicians and patients with optimal choices for individualized care. The acquisition was completed for an implied transaction value of approximately $700 million, financed with cash on hand and a financing facility with Blackstone.